Thank you to Masila, PolarOne and any others that have let us know you will be at the AGMs for Resverlogix and Zenith tomorrow and taking notes to share. It is very much appreciated from folks like me who won't be in attendance. Past notes from AGM and other meetings/conversations shared by the likes of Tada, Imtesty, Fouremm, Masila, Growacet, Tundup and others I am surely missing are so helpful. Hopefully the slide deck will be posted at the time of presenation even though the webcast won't be live and archive not available to view until later that evening.

For those in attendance, I just have a few issues to ask about in case they are not addressed in the presentation:

1) Back in the June 2018 news release, it was stated "Clinical data to date show that ZEN-3694 is active, safe, and well differentiated and will be presented at an upcoming scientific meeting." What scientific meeting (and when) will this data be presented? Is this just on the ZEN-3694 single agent Phase 1 trial or will this also include the Phase 1 ZEN-3694/enzalutamide combo trial data?

2) Is the CURATE.AI individualized dosing platform being applied to all (or at least some) of the patients in the Phase 2 enzalutamide/ZEN-3694 mCRPC trial? If CURATE.AI is not being used in Phase 2, is there a fixed dose of enzalutamide and ZEN-3694 being used in all patients in Phase 2 or does the investigator have discretion to alter the dose (amount per day) and frequency (i.e. daily dosing or intermittent dosing) in a patient in the trial?

3) Slide 15 of the March 2018 BIO-Europe presentation outlined several additional planned ZEN-3694 trials: Phase 1b/2a ZEN-3694 in combo with abiraterone for mCRPC, ZEN-3694+PARPi in HRD+/HRD- patients (breast, CRPC, ovarian), Phase 1b/2a ZEN-3694+fulvestrant in ER+ breast cancer, Phase 1b/2a: ZEN-3694 + PD1/PD-L1 Mab in Renal/Melanoma/HNSCC/NSCLC/Bladder, others. Which is the most likely to happen first and when?

Thanks,

BearDownAZ